Post-merger, Indalo raises $9M; Spark raising $331M; No word on Shkreli’s fate
→ A St. Louis-based biotech named Indalo Therapeutics — formerly Antegrin — has picked up the first $9 million of a planned $26 million investment, according to a Form D filed with the SEC. The filing includes a variety of high-profile VCs, including Ben Auspitz at F-Prime and Peter Barrett at Atlas. The company was created last fall through a merger of Antegrin Therapeutics and Cascadia Therapeutics. It’s focused on fibrosis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.